These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

813 related articles for article (PubMed ID: 34363606)

  • 61. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
    Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
    Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sodium-glucose co-transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction.
    Tiwary M; Milder TY; Stocker SL; Day RO; Greenfield JR
    Intern Med J; 2022 Oct; 52(10):1666-1676. PubMed ID: 35257458
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Uric acid and the cardio-renal effects of SGLT2 inhibitors.
    Bailey CJ
    Diabetes Obes Metab; 2019 Jun; 21(6):1291-1298. PubMed ID: 30762288
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
    Komuro I; Kadowaki T; Bodegård J; Thuresson M; Okami S; Yajima T
    Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():19-27. PubMed ID: 33835641
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Second revolution in cardiovascular prevention.
    Chiang CE; Wang KL; Cheng HM; Sung SH; Chao TF
    J Chin Med Assoc; 2020 Apr; 83(4):327-336. PubMed ID: 32101893
    [TBL] [Abstract][Full Text] [Related]  

  • 66. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: Impact of the 2020 KDIGO clinical practice guidelines.
    Ciardullo S; Trevisan R; Perseghin G
    Pharmacol Res; 2021 Apr; 166():105530. PubMed ID: 33675963
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [SGLT2 inhibitors in patients with chronic kidney disease : from clinical trials to guidelines and new prospects for clinical practice].
    Scheen AJ; Delanaye P
    Rev Med Liege; 2021 Mar; 76(3):186-194. PubMed ID: 33682388
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?
    Neuen BL; Jardine MJ; Perkovic V
    Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i48-i55. PubMed ID: 32003833
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia: A Review of the Evidence From Clinical Trials.
    Albakr RB; Sridhar VS; Cherney DZI
    Am J Kidney Dis; 2023 Dec; 82(6):737-742. PubMed ID: 37517546
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of chronic kidney disease.
    Sharaf El Din UAA; Salem MM; Abdulazim DO
    Nefrologia (Engl Ed); 2022; 42(4):390-403. PubMed ID: 36460429
    [TBL] [Abstract][Full Text] [Related]  

  • 72. SGLT2 Inhibitors: A New Therapeutical Strategy to Improve Clinical Outcomes in Patients with Chronic Kidney Diseases.
    Di Costanzo A; Esposito G; Indolfi C; Spaccarotella CAM
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240080
    [TBL] [Abstract][Full Text] [Related]  

  • 73. SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?
    Raschi E; Fadini GP; Diemberger I; Poluzzi E; De Ponti F
    Expert Opin Pharmacother; 2021 Apr; 22(5):647-650. PubMed ID: 33141609
    [No Abstract]   [Full Text] [Related]  

  • 74. Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease.
    Solomon J; Festa MC; Chatzizisis YS; Samanta R; Suri RS; Mavrakanas TA
    Pharmacol Ther; 2023 Feb; 242():108330. PubMed ID: 36513134
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Modeling the renoprotective mechanisms of SGLT2 inhibition in hypertensive chronic kidney disease.
    Clemmer JS; Yen TE; Obi Y
    Physiol Rep; 2023 Nov; 11(21):e15836. PubMed ID: 37957121
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials.
    Heerspink HJL; Vart P; Jongs N; Neuen BL; Bakris G; Claggett B; Vaduganathan M; McCausland F; Docherty KF; Jhund PS; Solomon SD; Perkovic V; McMurray JJV
    Diabetes Obes Metab; 2023 Nov; 25(11):3327-3336. PubMed ID: 37580309
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [IMPROVEMENT OF RENAL OUTCOMES WITH SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS].
    Schechter M; Mosenzon O
    Harefuah; 2021 Oct; 160(10):671-678. PubMed ID: 34689438
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Renal physiology of glucose handling and therapeutic implications.
    Cherney DZ; Kanbay M; Lovshin JA
    Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i3-i12. PubMed ID: 32003835
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
    Jhund PS; Solomon SD; Docherty KF; Heerspink HJL; Anand IS; Böhm M; Chopra V; de Boer RA; Desai AS; Ge J; Kitakaze M; Merkley B; O'Meara E; Shou M; Tereshchenko S; Verma S; Vinh PN; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Bengtsson O; Langkilde AM; Sjöstrand M; McMurray JJV
    Circulation; 2021 Jan; 143(4):298-309. PubMed ID: 33040613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.